Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: Mol Cell Neurosci. 2017 Apr 9;82:105–117. doi: 10.1016/j.mcn.2017.04.001

Figure 4.

Figure 4

Chronic treatment with paclitaxel does not reduce basal PKC α, βI or βII, immunoreactivity in cultured sensory neurons. (A, C, E) Representative western blot images showing immunoreactivity for PKC α, βI and βII in whole cell lysates in neurons treated with vehicle and paclitaxel (300 nM, 3 days). (B, D, F) Densitometry analysis showing no significant differences in PKC immunoreactivity normalized to actin in paclitaxel-treated (300 nM, 3 days) neurons compared to vehicle-treated neurons using a t-test (N = 3–4, a.u. ± SEM). Veh - Vehicle; Pac -Paclitaxel.